48,830
edits
m (→Organ specific: wikify) |
|||
Line 40: | Line 40: | ||
==Organ specific== | ==Organ specific== | ||
===Thyroid=== | ===Thyroid=== | ||
*TTF-1 (thyroid transcription factor-1). | *TTF-1 ([[thyroid]] transcription factor-1) -- +ve in thyroid gland malignancies. | ||
**Very good for breast vs. lung.<ref name=pmid18318581>{{cite journal |author=Jagirdar J |title=Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung |journal=Arch. Pathol. Lab. Med. |volume=132 |issue=3 |pages=384–96 |year=2008 |month=March |pmid=18318581 |doi= |url=http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=132&page=384}}</ref> | **Very good for [[breast]] vs. [[lung]].<ref name=pmid18318581>{{cite journal |author=Jagirdar J |title=Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung |journal=Arch. Pathol. Lab. Med. |volume=132 |issue=3 |pages=384–96 |year=2008 |month=March |pmid=18318581 |doi= |url=http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=132&page=384}}</ref> | ||
***Negative in squamous cell carcinoma of the lung (as with CK7 & CK20), though HMWK is usually positive. | ***Negative in squamous cell carcinoma of the lung (as with CK7 & CK20), though HMWK is usually positive. | ||
===Breast markers=== | ===[[Breast]] markers=== | ||
*GCDFP-15 (aka BRST2) -- specific, but NOT sensitive. | *GCDFP-15 (aka BRST2) -- specific, but NOT sensitive. | ||
*ER (estrogen receptor) - in normal breast. | *ER (estrogen receptor) - in normal breast. | ||
Line 54: | Line 54: | ||
*PSA - prostatic specific antigen. | *PSA - prostatic specific antigen. | ||
*PSAP - prostatic specific acid phosphatase. | *PSAP - prostatic specific acid phosphatase. | ||
*p63 - stains nuclei of basal cell in normal prostate. | *p63 - stains nuclei of basal cell in normal [[prostate]]. | ||
*34betaE12 - stains basals cells in normal prostate. | *34betaE12 - stains basals cells in normal prostate. | ||
*AMACR (racemase, P504S<ref>[http://www.antibodies-online.com/antibody/125649/P504S+alphaMethylacylCoA+Racemace+AMACR+Human/ http://www.antibodies-online.com/antibody/125649/P504S+alphaMethylacylCoA+Racemace+AMACR+Human/]</ref>) - present in adenocarcinoma (NOT in normal prostate). | *AMACR (racemase, P504S<ref>[http://www.antibodies-online.com/antibody/125649/P504S+alphaMethylacylCoA+Racemace+AMACR+Human/ http://www.antibodies-online.com/antibody/125649/P504S+alphaMethylacylCoA+Racemace+AMACR+Human/]</ref>) - present in adenocarcinoma (NOT in normal prostate). | ||
Line 87: | Line 87: | ||
*AFP (alpha-fetaprotein). | *AFP (alpha-fetaprotein). | ||
*Glypican-3. | *Glypican-3. | ||
**HCC stains with glypican 3, while liver with dysplastic changes and/or [[cirrhosis|cirrhotic changes]] does not.<ref>{{cite journal | author=Anatelli F, Chuang ST, Yang XJ, Wang HL. |title=Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy |journal=Am J Clin Pathol. |volume=130 |issue= 2 |pages= 219-23? |year= 2008 |pmid= 18628090 |doi= 10.1309/WMB5PX57Y4P8QCTY }}</ref> | **HCC stains with glypican 3, while [[liver]] with dysplastic changes and/or [[cirrhosis|cirrhotic changes]] does not.<ref>{{cite journal | author=Anatelli F, Chuang ST, Yang XJ, Wang HL. |title=Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy |journal=Am J Clin Pathol. |volume=130 |issue= 2 |pages= 219-23? |year= 2008 |pmid= 18628090 |doi= 10.1309/WMB5PX57Y4P8QCTY }}</ref> | ||
*HepPar-1 (hepatocytes paraffin antibody 1) - labels hepatocellular mitochondria.<ref name=pmid12502967>The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review. Lamps LW, Folpe AL. Adv Anat Pathol. 2003 Jan;10(1):39-43. Review. PMID 12502967.</ref> | *HepPar-1 (hepatocytes paraffin antibody 1) - labels hepatocellular mitochondria.<ref name=pmid12502967>The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review. Lamps LW, Folpe AL. Adv Anat Pathol. 2003 Jan;10(1):39-43. Review. PMID 12502967.</ref> | ||
Line 111: | Line 111: | ||
===Pancreas=== | ===Pancreas=== | ||
*CK17 - approx. 50% of | *CK17 - approx. 50% of [[pancreas|pancreatico]]biliary adenocarcinomas & patchy.<ref name=pmid11345833>{{cite journal |author=Goldstein NS, Bassi D |title=Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold |journal=Am. J. Clin. Pathol. |volume=115 |issue=5 |pages=695–702 |year=2001 |month=May |pmid=11345833 |doi=10.1309/1NCM-46QX-3B5T-7XHR |url=}}</ref> | ||
*CK19.<ref name=pmid18318589>{{cite journal |author=Geller SA, Dhall D, Alsabeh R |title=Application of immunohistochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon, and pancreas |journal=Arch. Pathol. Lab. Med. |volume=132 |issue=3 |pages=490–9 |year=2008 |month=March |pmid=18318589 |doi= |url=}}</ref> | *CK19.<ref name=pmid18318589>{{cite journal |author=Geller SA, Dhall D, Alsabeh R |title=Application of immunohistochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon, and pancreas |journal=Arch. Pathol. Lab. Med. |volume=132 |issue=3 |pages=490–9 |year=2008 |month=March |pmid=18318589 |doi= |url=}}</ref> | ||
edits